Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

BACKGROUND: In TEMPO 3:4, the vasopressin V2 receptor antagonist tolvaptan slowed total kidney volume (TKV) growth and estimated glomerular filtration rate (eGFR) decline relative to placebo. METHODS: TEMPO 4:4 was designed to provide an additional 2 years of data on the long-term safety and efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres, Vicente E, Chapman, Arlene B, Devuyst, Olivier, Gansevoort, Ron T, Perrone, Ronald D, Dandurand, Ann, Ouyang, John, Czerwiec, Frank S, Blais, Jaime D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019005/
https://www.ncbi.nlm.nih.gov/pubmed/28379536
http://dx.doi.org/10.1093/ndt/gfx043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019005/
https://www.ncbi.nlm.nih.gov/pubmed/28379536
http://dx.doi.org/10.1093/ndt/gfx043

Ejemplares similares